You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP
SBC: TERAPIO Topic: NCIOral mucositis (OM) is a common side effect in oncology patients receiving radiation treatment. Mucosal breakdown causes pain which leads to increased use of narcotic analgesics and restriction of food intake. OM often progresses to septicemia, increasinghospital stays and costs, and ultimately discontinuation of radiotherapy. This impacts overall effectiveness of cancer therapy so development of ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP
SBC: Omm Scientific, Inc Topic: NCIRadiation insensitive tumors that become radiation resistant are often also invasive, metastatic, and responsible for most cancer deaths. Here, the long term objective is to complete clinical evaluation of an inhibitor of a new target (V-ATPase) that sensitizes tumors but not healthy tissues to radiation and inhibits multiple aspects of tumor metabolism and therapeutic resistance. Development o ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP
SBC: SUVICA INC Topic: NCIThe long-term goal of this proposal is to discover and develop small molecule drugs against Head and Neck Cancers (HNC). The focus is on drug candidates that target processes critical for repopulation after radiation treatment. The current proposal is to perform preliminary pharmacokinetics and toxicity studies and test the efficacy of a proprietary drug candidate on preclinical models of human HN ...
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 229: PHASE I ERK DEV. OF MOLECULAR PHARMACODYNAMIC ASSAYS
SBC: BIOASSAY SYSTEMS, LLC Topic: N/AExtracellular-signal-regulated kinase (ERK) is a key protein kinase of the MAP kinase pathway and plays a key role in cell proliferation, differentiation and migration. The MAPK cascade presents many targets for the development of novel and safer cancer therapies. Despite a lot of progress in the discovery of therapeutic agents, a pharmacodynamic assay for ERK is missing. In this proposed research ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
TOPIC #384- PHASE I (FAST TRACK) SBIR CONTRACT- FINCARE: ENABLING PROVIDERS AND PATIENTS TO MAKE INFORMED CHOICES AND MINIMIZED FINANCIAL HARDSHIP
SBC: CARE PROGRESS LLC Topic: NCIThis research project seeks to create innovative software that aids healthcare providers to calculate the out of pocket costs of patients receiving cancer treatmentThe goals of this SBIR project are to leverage the insights of stakeholderssubject matter experts and industry standards to create a software system that can be integrated into the workflow of providersIf we are successfulhealthcare pro ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
TOPIC #384- PHASE I (FAST TRACK) SBIR CONTRACT- FINCARE: ENABLING PROVIDERS AND PATIENTS TO MAKE INFORMED CHOICES AND MINIMIZED FINANCIAL HARDSHIP
SBC: CARE PROGRESS LLC Topic: 384This research project seeks to create innovative software that aids healthcare providers to calculate the out-of-pocket costs of patients receiving cancer treatment. The goals of this SBIR project are to leverage the insights of stakeholders, subject matter experts and industry standards to create a software system that can be integrated into the workflow of providers. If we are successful, health ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 409 PHASE I FY20 SBIR CONTRACT- TOPIC 409- INTELLIGENT AUTOMATION INC.
SBC: Intelligent Automation, Inc. Topic: 409Cancer patients experience substantial functional impairments during and after treatments, often requiring rehabilitation and exercise interventions. However, a functional assessment of the specific deficits and impairments in the individual is needed to inform exercise therapy. The oncology workforce is challenged in its capacity to conduct such functional assessment, therefore limiting the abili ...
SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 316 PHASE I: GENETIC ANALYSIS OF CTCS AT THE SINGLE CELL LEVEL; HHSN261201
SBC: Cellecta, Incorporated Topic: NCINot Available
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 423 (PHASE II): AN INTEGRATED MULTI-LEVEL DECISION SUPPORT PLATFORM TO ADDRESS PATIENT-CENTERED AND EVIDENCE-BASED SOCIAL DETERMINANTS OF HEALTH AMONG CANCER PATIENTS.
SBC: PISTEVO DECISION LLC Topic: 423A strong body of evidence suggests that addressing Social Determinants of Health (SDH) within healthcare systems advances cancer treatment adherence and reduces disparities in outcomes; however, few studies actually intervene and provide resources to meet cancer patients’ SDH. Integrating SDH with clinical information within operational Clinical Decision Support (CDS) systems built into Electron ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 296 PHASE II; A SYSTEM FOR ENCOURAGING ADOPTION OF NEW METHODS FOR ACTIVIT
SBC: EveryFit, Inc. (DBA "QMedic") Topic: NCISPADES: A system for Encouraging Adoption of New methods for Activity Monitoring PUBLIC HEALTH RELEVANCE
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health